Tulynode Biosciences

Tulynode Biosciences is a private San Diego biotechnology company developing autologous immune-cell therapies for oncology. Its core approach appears to center on an extracorporeal cell-activation device platform called Immuno-Pod, designed to expose a patient's immune cells to tumor material outside the body and then return activated cells to the patient. Publicly available information indicates the company has operated largely in stealth mode, with limited disclosure of a formal clinical pipeline. Patent and licensing materials suggest a focus on minimally manipulated, tumor-specific immune activation rather than conventional ex vivo cell-engineering workflows. Overall, Tulynode appears to be an early-stage immuno-oncology platform company built around device-enabled autologous cell therapy concepts.